Is Inulin Gut Randomized Trial safe?

The current Migaku evidence database contains 2 reusable source documents for Inulin Gut Randomized Trial. This answer focuses on safety, limits, and clinician-discussion contexts. - Our previous work demonstrated that patients with OLP exhibit reduced gut microbial diversity and a marked depletion of butyrate‑producing bacteria compared with healthy individuals []. [Nambu Koki (2026); evidence level 2] - Given that OLP is characterised by dysbiosis with reduced butyrate‑producing bacteria, inulin supplementation may help restore microbial balance and modulate immune responses. [Nambu Koki (2026); evidence level 2] - The findings of this trial are expected to provide foundational evidence for prebiotic supplementation as an adjunctive microbiota-directed strategy in OLP. [Nambu Koki (2026); evidence level 2] - 1 2 3 Oral lichen planus (OLP) is a chronic inflammatory disease of the oral mucosa characterised by T-cell–mediated immune dysregulation [,]. [Nambu Koki (2026); evidence level 2] - Next, we integrate these fermentation and microbial-utilization features to explain the rationale for co-administration with long-chain inulin and review the available preclinical evidence. [Fujii Tadashi (2026); evidence level 3] Evidence levels are sorting aids, not final clinical grades. Level 1 usually indicates systematic-review style evidence, level 2 indicates randomized trials or public-health guidance, and lower levels need more cautious wording. This page is educational. People with medical conditions, pregnancy, medication use, or unusual symptoms should ask a qualified clinician before changing supplements, medication, or treatment routines.